| Outcome Measures: |
Primary: Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF), ml/min, 8 weeks | Secondary: Renal damage, measured by urine biomarkers, enzyme immuno assay, 8 weeks|Renal tubular function, e.g. percentage (%), 8 weeks|Blood Pressure, mmHg, 8 weeks | Other: Body anthropometrics: body weight, height, body mass index, waist circumference, kilogram, meters, centimeters, 8 weeks|Body fat content, e.g. percentage (%), 8 weeks|Glycemic variables, e.g. mmol/l, mmol/mol, 8 weeks|Lipid spectrum, e.g. mmol/l, 8 weeks|Inflammatory markers, e.g. nmol/l, 8 weeks|Systemic hemodynamic variables, e.g. ml/min, 8 weeks|Heart rate, beat per minute, 8 weeks|Microvascular function, e.g. count, 8 weeks|Arterial stiffness, e.g. augmentation index, 8 weeks
|
